KBC Group NV Sells 86,325 Shares of Merck & Co., Inc. $MRK

KBC Group NV reduced its holdings in Merck & Co., Inc. (NYSE:MRK) by 7.1% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,131,286 shares of the company’s stock after selling 86,325 shares during the quarter. KBC Group NV’s holdings in Merck & Co., Inc. were worth $145,370,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares during the period. Sivia Capital Partners LLC lifted its holdings in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after buying an additional 3,941 shares during the period. Diversify Advisory Services LLC grew its position in shares of Merck & Co., Inc. by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after buying an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC grew its position in shares of Merck & Co., Inc. by 22.2% in the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after buying an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Merck & Co., Inc. by 111.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after buying an additional 359,356 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock opened at $152.43 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The business has a 50-day moving average price of $128.09 and a two-hundred day moving average price of $121.23. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $154.49. The company has a market cap of $376.07 billion, a P/E ratio of 121.94, a PEG ratio of 6.58 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on MRK shares. Wells Fargo & Company raised their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 8th. Morgan Stanley upgraded Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $116.00 to $179.00 in a report on Thursday. UBS Group increased their target price on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday. The Goldman Sachs Group raised their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday. Finally, Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Fifteen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $144.10.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. The trade was a 62.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total value of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares in the company, valued at $14,501,282.21. The trade was a 9.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last 90 days. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.